NovaBay's Non-Antibiotic Anti-Infective Shows Efficacy In Impetigo Trial
Executive Summary
NovaBay is a step closer to commercializing the first non-antibiotic for treating an infection typically treated with antibiotics, now that its topical gel yielded a 90 percent cure rate in a Phase IIa proof-of-concept trial against impetigo
You may also be interested in...
Still Waiting To Launch In U.S., NovaBay Sees Big Opportunity For Advanced Wound Care In Southeast Asia
While getting ready to launch FDA-approved wound-healing product NeutroPhase in the U.S., NovaBay also has expanded a commercialization partnership with Pioneer Pharma to add 13 Southeast Asian countries and territories to a collaboration once exclusive to China.
Still Waiting To Launch In U.S., NovaBay Sees Big Opportunity For Advanced Wound Care In Southeast Asia
While getting ready to launch FDA-approved wound-healing product NeutroPhase in the U.S., NovaBay also has expanded a commercialization partnership with Pioneer Pharma to add 13 Southeast Asian countries and territories to a collaboration once exclusive to China.
Altabax Review Highlights Ethical Use Of Placebo In Pediatric Populations
GlaxoSmithKline’s pivotal trial for Altabax provided strong evidence that it could be ethical to use a placebo and withhold treatment for dermatological indications – even in a pediatric population – as long as safety measures were employed, FDA reviewers concurred.